Domingo Liotta Hospital, Houston, Texas. First Clinical use. 1966 (August 8): Liotta-DeBakey LVAD in a paracorporeal position in cardiogenic shock postcardiotomy, Methodist Hospital, Houston, Texas. First successful clinical use. 1969 (April 4): Liotta-Cooley Total Artificial Heart, Texas Heart Institute, Houston, Texas. First clinical use. http://www.texasheartinstitute.org/Research/Devices/liotta.cfm. This device was stolen from the lab of Dr. Michael E. DeBakey by Liotta. Dr. Cooley was not involved in any way in its development. The device had not been successful in animal experiments, and while the patient had the artificial heart in place he developed multiple system organ failure, as the experimental animals had, and died
Human artificial chromosome resulted in a human artificial chromosome that is mitotically stable. 21HAC was also able to be transferred into cells from a variety of species (mice, chickens, humans). Using 21HAC, researchers were able to insert a herpes simplex virus- thymidine kinase coding gene into tumor cells. This "suicide gene" is required to activate many antiviral medications. These targeted tumor cells were successfully, and selectively, terminated by the antiviral drug ganciclovir in a population including healthy cells. This research opens a variety of opportunities for using HACs in gene therapy. In 2011, researchers formed a human artificial chromosome by truncating chromosome 14.